TFAM

Across TCGA pan-cancer cohorts, TFAM mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TFAM data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher TFAM mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TFAM expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

GBM, CCRCC, and LSCC are the cancer types where TFAM mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.647	0.418	.003	25	view →
CCRCC	OS	Median	II,III,IV	0.705	0.933	.008	23	view →
LSCC	DFS	Median	II,III,IV	0.969	0.878	.017	13	view →
PDAC	DFS	Tertile	IV	0.245	0.726	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TFAM–GBM (OS)

Open the GBM breakdown →